The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.
Milrinone elimination will be verify with blood and urine samples analysis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
40
Inhaled milrinone 5 mg (as for the injectable solution)
Montreal Heart Institute
Montreal, Quebec, Canada
Study the elimination rate of milrinone administered by inhalation
Time frame: up to 24 hours
Demonstrate the presence or absence of hemodynamic and echographic effects observed after inhalation of milrinone
hemodynamic values evaluated will be: central venous pressure, systolic and diastolic pulmonary pressure, wedge, cardiac output, cardiac frequency, systolic and diastolic pressure, SaO2, EtCO2. Patient will also have arterial and venous gaz. Echographic values will be evaluated to see the cardiac fonction: left and right ventricular systolic and diastolic function and valvular function.
Time frame: 15 min after the of study drug administration
Confirmation of the safety of inhaled milrinone
Verification of the absence of deleterious effects on cardiac output and systemic arterial pressure.
Time frame: 24 hours after cardiac surgery
Determination of the efficacy of inhaled milrinone in the treatment of pulmonary hypertension
Efficacy in the treatment of pulmonary hypertension is defined as a reduction of the mean pulmonary pressure of 10-20 %
Time frame: 15 min after end of milrinone administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.